Powering the future of gene therapy: insights on achieving scalable AAV production at 1000L

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Powering the future of gene therapy: insights on achieving scalable AAV production at 1000L

Live30 webinars pack the latest innovations and applications into a data-rich 30-minute session.

As AAV gene therapy matures as a viable modality, innovators are moving beyond rare diseases and are now considering indications with larger patient populations. This necessitates the need for larger production batches with consistent yield and product quality.

In this webinar, experts from Mirus Bio and MilliporeSigma’s viral vector CDMO will share insights from a successful AAV8 production in a 1000L single-use bioreactor, highlighting the key innovations and expertise that made this milestone possible. Learn how a robust platform process seamlessly integrates transfection complex stabilizer to replicate bench-scale yields at the 1000L scale while navigating potential pitfalls that are encountered during scale-up.

Join us to discover how to power the next generation of gene therapies by delivering confidence in every batch.

Attend this webinar to:

Review real-world scale-up data from a successful AAV8 production run in a 1000L single-use bioreactor, including yield and quality outcomes
Understand how transfection reagent integration was optimized within a platform process to replicate bench-scale performance at commercial scale
Identify common pitfalls encountered during AAV scale-up and learn practical strategies to address them before they affect your timeline or batch quality
Gain a framework for evaluating whether your current platform process is compatible with large-scale manufacturing demands

Sandy Tseng

Field Application Scientist at Mirus Bio

Sandy Tseng has been a key member of the Technical Support team at Mirus Bio since 2019, where she collaborates closely with scientists to troubleshoot and optimize their gene delivery experiments and processes. Prior to joining Mirus Bio, Sandy completed her doctoral research on the regulation of eukaryotic gene expression at the University of Wisconsin-Madison. Her expertise bridges emerging biotechnology with practical applications in biomanufacturing.

Hugh Murray

Upstream Process Development Manager at MilliporeSigma

Hugh is the Upstream Process Development Manager at MilliporeSigma's Viral Vector CDMO in Carlsbad, CA, with over a decade of experience designing and scaling mammalian suspension processes for biologics and gene therapy. He specializes in DoE methodology, predictive modeling, automated micro-bioreactor and liquid handling platforms, and scaling bench-scale processes to large-scale single-use bioreactors -leading the development of workflows that can take a client's "gene and a dream" into clinical phase manufacturing rapidly and efficiently. Prior to the viral vector space, Hugh worked in mAb process development, characterization, and validation at Tanvex BioPharma Inc., including authoring BLA CMC sections for biosimilar approval and managing MSAT teams during phase III clinical material production.

In 35 Days

You have registered for this webinar